The purpose of this study is to use a genotype-first approach to explore highly penetrant, autosomal dominant cardiovascular diseases with external features, the RASopathies and Marfan syndrome (MFS), using biobank data.
This study uses exome sequencing and corresponding phenotypic data from Mount Sinai’s BioMe (n = 32,344) and the United Kingdom Biobank (UKBB; n = 49,960). Variant curation identified pathogenic/likely pathogenic (P/LP) variants in RASopathy genes and FBN1.
Twenty-one subjects harbored P/LP RASopathy variants; three (14%) were diagnosed, and another 46% had ≥1 classic Noonan syndrome (NS) feature. Major NS features (short stature [9.5% p = 7e-5] and heart anomalies [19%, p < 1e-5]) were less frequent than expected. Prevalence of hypothyroidism/autoimmune disorders was enriched compared with biobank populations (p = 0.007). For subjects with FBN1 P/LP variants, 14/41 (34%) had a MFS diagnosis or highly suggestive features. Five of 15 participants (33%) with echocardiographic data had aortic dilation, fewer than expected (p = 8e-6). Ectopia lentis affected only 15% (p < 1e-5).
Substantial fractions of individuals harboring P/LP variants with partial or full phenotypic matches to a RASopathy or MFS remain undiagnosed, some not meeting diagnostic criteria. Routine population genotyping would enable multidisciplinary care and avoid life-threatening events.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014;156:872–877.
Alver M, et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genet Med. 2019;21:1173–1180.
Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381:333–342.
Pyeritz RE. Recent progress in understanding the natural and clinical histories of the Marfan syndrome. Trends Cardiovasc Med. 2016;26:423–428.
Aoki Y, Niihori T, Inoue S-i, Matsubara Y. Recent advances in RASopathies. J Hum Genet. 2016;61:33–39.
Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25:161–179.
Von Kodolitsch Y, Raghunath M, Nienaber C. Marfan syndrome: prevalence and natural course of cardiovascular manifestations. Z Kardiol. 1998;87:150.
Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–192.
Wildeman M, Van Ophuizen E, Den Dunnen JT, Taschner PE. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum Mutat. 2008;29:6–13.
Freeman PJ, Hart RK, Gretton LJ, Brookes AJ, Dalgleish R. VariantValidator: accurate validation, mapping, and formatting of sequence variation descriptions. Hum Mutat. 2018;39:61–68.
Gelb BD, et al. ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. Genet Med. 2018;20:1334–1345.
Baudhuin LM, Kluge ML, Kotzer KE, Lagerstedt SA. Variability in gene-based knowledge impacts variant classification: an analysis of FBN1 missense variants in ClinVar. European J Hum Genet. 2019;27:1550–1560.
Muiño-Mosquera L, et al. Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the Interpretation of Sequenced Variants in the FBN1 Gene for Marfan Syndrome: proposal for a disease-and gene-specific guideline. Circ Genom Precis Med . 2018;11:e002039.
Loeys BL, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476–485.
Desmet F-O, et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67–e67.
Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol. 1997;4:311–323.
Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004;11:377–394.
Kopanos C, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978.
Devereux RB, et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons≥ 15 years of age. Am J Cardiol. 2012;110:1189–1194.
Santos FP, et al. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020;34:799–810.
Lo F-S, et al. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.Eur J Pediatr. 2009;168:919.
Van Der Burgt I, et al. Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet. 1994;53:187–191.
Prendiville TW, et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child. 2014;99:629–634.
Gripp KW, et al. Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: structural brain anomalies and myelofibrosis. Am J Med Genet A. 2013;161:2420–2430.
Rybczynski M, et al. Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome. Am J Cardiol. 2010;106:1048–1053.
Lacro RV, et al. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013;165:828–35. e3.
Nahum Y, Spierer A. Ocular features of Marfan syndrome: diagnosis and management. Isr Med Assoc J. 2008;10:179.
Haggerty CM, et al. Genomics-first evaluation of heart disease associated with titin-truncating variants. Circulation. 2019;140:42–54.
Haggerty CM, et al. Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing. Genet Med. 2017;19:1245–1252.
Park J. et al. A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. Genet Med. 2020;22:102–111.
Noonan JA. Associated noncardiac malformations in children with congenital heart disease. J Pediatr. 1963;63:468–470.
Noonan JA, Raaijmakers R, Hall B. Adult height in Noonan syndrome. Am J Med Genet A. 2003;123:68–71.
Alpendurada F, et al. Evidence for Marfan cardiomyopathy. Eur J Heart Fail. 2010;12:1085–1091.
Sharland M, Burch M, McKenna W, Paton M. A clinical study of Noonan syndrome. Arch Dis Child. 1992;67:178–183.
Lee MJ, et al. Hashimoto thyroiditis with an unusual presentation of cardiac tamponade in Noonan syndrome. Korean J Pediatr. 2016;59:S112.
Amoroso A, et al. The unusual association of three autoimmune diseases in a patient with Noonan syndrome. J Adolesc Health. 2003;32:94–97.
Svensson J, Carlsson A, Ericsson UB, Westphal O, Ivarsson SA. Noonan’s syndrome and autoimmune diseases. J Pediatr Endocrinol Metab. 2003;16:217–218.
Uehara T, Hosogaya N, Matsuo N, Kosaki K. Systemic lupus erythematosus in a patient with Noonan syndrome‐like disorder with loose anagen hair 1: more than a chance association. Am J Med Genet A. 2018;176:1662–1666.
Bader-Meunier B, et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum. 2013;43:217–219.
Quaio CR, et al. Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies. Am J Med Genet A. 2012;158:1077–1082.
We acknowledge the participants enrolled in BioMe and UKBB, without whom this research would not be possible. We also acknowledge the ongoing work of the Mount Sinai’s Charles Bronfman Institute for Personalized Medicine for ongoing curation of BioMe. This work was supported in part by United States Public Health Service (USPHS) grant to R.D. (GM124836 and HL139865), B.D.G. (HL135742), and A.R.K. (HL140083) and grants from Italian Association for Cancer Research (IG21614), European Joint Programme on Rare Diseases (NSEuroNet) to M.T. J.D.B is supported as senior clinical researcher by the Research Foundation Flanders and holds a Grant for Medical Research from the Baillet Latour Funds. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. This work was also supported in part through the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland. This research has been conducted using the UK Biobank Resource under application number 16218.
B.D.G. and M.T. receive royalties for genetic testing of the RASopathies from Correlegan, GeneDx, LabCorp, and Prevention Genetics. D.R.S. performs contract telegenetics services for Genome Medical, Inc., in accordance with relevant National Cancer Institute ethics policies. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wenger, B.M., Patel, N., Lui, M. et al. A genotype-first approach to exploring Mendelian cardiovascular traits with clear external manifestations. Genet Med (2020). https://doi.org/10.1038/s41436-020-00973-2
- exome sequencing
- Mendelian disorders
- cardiovascular system
- genotype–phenotype correlations
- precision medicine